Short-term efficacy of early percutaneous cholecystostomy for pancreatitis and factors associated with recurrence and mortality

Table 6 Pre-percutaneous cholecystostomy comparisons between the nonfatal and fatal groups, n (%)

Variables	Nonfatal group (n = 47)	Fatal group (n = 7)	Single factor analysis	Multi-factor analysis
			P value	P value [OR (95%CI)]
Age (years)	61.11 ± 20.27	73.43 ± 21.31	0.142
Sex			0.443
Male	25 (53.2)	5 (71.4)
Female	22 (46.8)	2 (28.6)
BMI	25.37 ± 3.13	25.13 ± 4.68	0.861
RAC classification			0.102
Moderately severe	25 (53.2)	1 (14.3)
Severe	22 (46.8)	6 (85.7)
Days of hospitalization (days)	16.6 ± 9.76	21.86 ± 8.69	0.184
Fever (≥ 37.3 °C)	24 (51.1)	6 (85.7)	0.117
WBC (× 109/L)	13.25 (10.88-16.52)	16.28 (9.77-18.58)	0.495
NEU (%)	87.2 (82.8-90.7)	90.3 (88.3-91.6)	0.116
ALT (U/L)	36 (23.7-115)	59 (48-81)	0.212
GGT (U/L)	108 (52-265)	105 (47-162)	0.757
TBIL (μmol/L)	25.5 (16.7-54.3)	34.1 (29.5-36.2)	0.374
DBIL (μmol/L)	3 (0-14)	2 (0-8.5)	0.799
IBIL (μmol/L)	14.3 (8.6-30.3)	13.1 (4.2-23.5)	0.361
AMS (U/L)	398 (152-1051)	173 (148-1087)	0.643
Gallbladder width (cm)	3.6 (3-4.1)	3.4 (2.7-4.9)	0.918
CTSI	3 (1-5)	3 (1-5)	0.821
CCI	4 (2-5)	6 (5-8)	0.001a	0.021 [2.397 (1.139-5.047)]
Congestive heart failure	2 (4.3)	0	1
Diabetes mellitus (no comorbidities)	13 (27.7)	1 (14.3)	0.771
Solid tumors (no metastases)	2 (4.3)	1 (14.3)	0.346
Cerebrovascular disease	7 (14.9)	4 (57.1)	0.037a	0.659 [1.631 (0.186-14.336)]
History of pancreatitis	11 (23.4)	1 (14.3)	0.957
Hypertension	22 (46.8)	3 (42.9)	1

^aP < 0.05.

PC: Percutaneous cholecystostomy; BMI: Body mass index; RAC: Revised Atlanta classification; WBC: White blood cell; NEU: Neutrophil; ALT: Alanine aminotransferase; GGT: Gamma-glutamyl transferase; TBIL: Total bilirubin; DBIL: Direct bilirubin; IBIL: Indirect bilirubin; AMS: Amylase; CTSI: Computed tomography severity index; CCI: Charlson Comorbidity Index; OR: Odds ratio; CI: Confidence interval.